Anida Pharma Inc.
Anida Pharma is dedicated to redefining ocular disease treatment by developing multi-targeting drugs for early intervention in both corneal and retinal diseases. Their mission is to develop therapies that are easy to apply, safe, and effective, aiming to prevent irreversible vision loss through innovative eye drop treatments. The company leverages its deep understanding of endogenous protective mechanisms to create novel therapies that slow or prevent disease progression, with a focus on conditions like retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
Industries
Nr. of Employees
small (1-50)
Anida Pharma Inc.
Cambridge, Massachusetts, United States, North America
Products
Modified endogenous neuroprotective lipid eye-drop therapeutic
A formulated, eye-drop-delivered modified neuroprotective lipid agonist designed to activate endogenous protective pathways in corneal and retinal tissues, with demonstrated preclinical efficacy and tolerability.
Modified endogenous neuroprotective lipid eye-drop therapeutic
A formulated, eye-drop-delivered modified neuroprotective lipid agonist designed to activate endogenous protective pathways in corneal and retinal tissues, with demonstrated preclinical efficacy and tolerability.
Expertise Areas
- Ophthalmic drug development
- Preclinical translational models (ocular and CNS)
- Topical ocular delivery and formulation
- Neuroprotection and inflammation biology
Key Technologies
- Lipid-derived small-molecule neuroprotective agonists
- Topical ocular (eye-drop) delivery with posterior-segment penetration
- Translational animal models (rabbit, mouse, large-eye species)
- Preclinical toxicology and IND-enabling studies